Cilofexor misses primary NASH endpoint, improves liver function in combination therapy

Results from the phase 2 ATLAS study showed that neither monotherapy nor combined therapy with cilofexor reached the endpoint of significant improvement in fibrosis stage without worsening of nonalcoholic steatohepatitis, according to a press release from Gilead Sciences.However, patients treated with a combination of the acetyl-CoA carboxylase inhibitor firsocostat and the farnesoid X receptor agonist cilofexor achieved improvements in multiple response measures of fibrosis and liver function compared with placebo.“This trial provides novel data showing consistent improvements in liverRead More

Share on facebook
Share on twitter
Share on linkedin